Lexicon to Present Study Results Relating to Sotagliflozin and LX9211 at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD)
September 26, 2023 09:00 ET
|
Lexicon Pharmaceuticals, Inc.
INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure LX9211 is an investigational, non-opioid treatment for diabetic peripheral neuropathic pain THE WOODLANDS, Texas,...
Lexicon Pharmaceuticals to Participate in the H.C. Wainwright & Co. 25th Annual Global Investment Conference
September 07, 2023 16:30 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the H.C. Wainwright & Co. 25th Annual Global Investment...
Lexicon Announces Series of Presentations Relating to LX9211, Its Investigational Drug for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)
September 07, 2023 09:00 ET
|
Lexicon Pharmaceuticals, Inc.
Five upcoming scientific presentations will add to the body of evidence supporting the advancement of LX9211 into late-stage development Phase 2b dose optimization study planning underway, with...
Lexicon to Present Analyses of INPEFA™ (sotagliflozin) Clinical Study Results and Changing Patterns of Heart Failure Diagnoses at the European Society of Cardiology (ESC) Congress 2023
August 21, 2023 09:00 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that analyses of clinical study results relating to INPEFA™...
Published Analysis of Sotagliflozin (INPEFA(TM)) Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure
August 08, 2023 09:00 ET
|
Lexicon Pharmaceuticals, Inc.
Post-Hoc Analysis of SOLOIST-WHF Clinical Data Published in Journal of the American College of Cardiology: Heart Failure Risk Reductions of Approximately 50% Demonstrated for Heart Failure...
Lexicon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
August 03, 2023 16:01 ET
|
Lexicon Pharmaceuticals, Inc.
INPEFATM (sotagliflozin) receives FDA approval for the treatment of heart failure INPEFA granted broad label across full range of left ventricular ejection fraction, including...
Lexicon Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 3, 2023
July 28, 2023 16:01 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, July 28, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2023 financial results on Thursday, August 3rd, 2023 after the...
Lexicon Elects Diane E. Sullivan to Board of Directors
July 28, 2023 08:00 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, July 28, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Diane E. Sullivan has been elected to its Board of Directors. Ms....
Lexicon Announces Planned Advancement of LX9211 Into Late-Stage Development
June 23, 2023 20:45 ET
|
Lexicon Pharmaceuticals, Inc.
First late-stage study will be a Phase 2b dose optimization study, with extension to run in parallel with next-stage Phase 3 studies Feedback obtained from U.S. Food and Drug Administration (FDA) ...
Lexicon to Present Study Results Relating to LX9211 and INPEFA™ (Sotagliflozin) at the American Diabetes Association’s 83rd Scientific Sessions
June 20, 2023 08:00 ET
|
Lexicon Pharmaceuticals, Inc.
LX9211 is an investigational, non-opioid treatment for diabetic peripheral neuropathic pain INPEFA recently approved for treatment of heart failure THE WOODLANDS, Texas, June 20, 2023 (GLOBE...